Page 13 - ஜப்பான் அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kaken Has Filed an Application in Japan for Regulatory Approval of KMW-1 Tokyo, June 28, 2021 - Kaken Pharmaceutical Co., Ltd. ( Kaken , head office Bunkyo-ku, Tokyo; President and Representative Director Hiroyuki Horiuchi) announces that it has submitted a new drug application to Japan s Ministry of Health, Labour and Welfare to seek manufacturing and marketing approval of KMW-1 for the removal of burn eschar. KMW-1 is a topical agent composed of a concentrate of proteolytic enzymes extracted from the stem of the pineapple plant. KMW-1 provides selective and quick removal of dead or damaged tissues, known as eschar, in approximately four hours after application, without harming the surrounding healthy tissues.

Bunkyo kuSouth koreaHiroyuki horiuchiJapan ministry of healthKaken pharmaceutical co ltdMediwound ltdRepresentative director hiroyuki horiuchiபுங்கயோ குதெற்கு கொரியாஜப்பான் அமைச்சகம் ஆஃப் ஆரோக்கியம்